- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT04579848
Metotrexát eróziós gyulladásos kéz osteoarthritisben (MERINO)
A metotrexát EROSÍV gyulladásos osteoarthritisben (MERINO) Trial: Randomizált, placebo-kontrollos vizsgálat a metotrexát klinikai hatékonyságának és biztonságosságának vizsgálatára az eróziós gyulladásos kéz osteoarthritisben.
A placebo-controlled randomized controlled trial exploring the effect of methotrexate on pain, function and structural outcomes in erosive inflammatory hand osteoarthritis.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
The trial will include Norwegian adult males and females with symptomatic erosive inflammatory hand osteoarthritis.
Participants will be randomized 1:1 to either:
- Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks (intervention group). Dosage can be reduced to as low as 10 mg if higher doses are not tolerated.
- Placebo (control group).
Both arms will receive folic acid 1mg daily.
The treatment duration for both groups is 52 weeks.
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- 4. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
-
Oslo, Norvégia
- Diakonhjemmet Hospital
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Finger joint pain 40-80 on 0-100 visual analog scale (VAS) with insufficient pain relief from, inability to tolerate or contra-indications to oral paracetamol and/or NSAIDs, and hand symptoms (pain, aching, or stiffness) on most days the previous 6 weeks before randomization.
- Hand OA according to the American College of Rheumatology (ACR) criteria, at least 1 distal (DIP) or proximal interphalangeal (PIP) joint of the 2nd-5th finger with radiographic pre-erosive (J-phase) or erosive disease (E-phase) according to the Verbruggen-Veys anatomical phase system, and at least two DIP/PIP joints with power Doppler signal of at least grade 1 or grey-scale synovitis of at least grade 2 on ultrasound.
Exclusion Criteria:
A full list of the exclusion criteria for this study comprised the following:
-
Contraindications to methotrexate:
- Abnormal renal function, defined as serum creatinine >142 µmol/L in women and >168 µmol/L in men, or a glomeruli filtration rate (GFR) <40 mL/min/1.73 m2.
- Abnormal liver function, defined as transaminases above the upper normal limit, active or previous hepatitis B or C infection, or known cirrhosis
- Lung fibrosis (maximum 6 months old x-ray), active infection, or reduced hematopoiesis (i.e. anemia, leukopenia and/or thrombocytopenia).
- Planned pregnancy within 18 months after screening (men/women), and pregnancy, breastfeeding, or insufficient anti-conception therapy for female fertile participants. Contraception should be maintained during treatment and until the end of systemic exposure, i.e. 3 months after methotrexate discontinuation. Sufficient anti-conception therapy consists of intra-uterine device (coil) or hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections).
- Alcohol or other drug abuse in the last year.
- Intolerance to lactose.
-
Chronic inflammatory rheumatic diseases (such as rheumatoid arthritis and psoriatic arthritis or gout), active inflammatory bowel disease, or positive rheumatoid factor or anti-CCP antibodies.
-
Other severe co-morbidities such as hemochromatosis, fibromyalgia, psoriasis, blood dyscrasias, and coagulation disorders, history of malignancy (except successfully treated squamous or basal cell skin carcinoma), uncontrolled diabetes mellitus, severe hypertension, unstable ischemic heart disease, severe heart failure, severe pulmonary disease, severe and/or opportunistic infections and/or chronic infections, active tuberculosis, positive human immunodeficiency virus (HIV) status, recent stroke, bone marrow hypoplasia, or demyelinating diseases of the central nervous system.
-
Other likely causes of hand symptoms: thoracic outlet syndrome, carpal tunnel disease, diabetic cheiropathy, injury in finger joints previous 6 months, or palmar tenosynovitis/trigger finger.
-
Oral or intra-muscular steroids in the previous month
-
Intra-articular treatments or aspirations of any kind of any joint in the hands 3 months before inclusion
-
Analgesics or NSAIDs, unless stable dosage for ≥1 month.
-
Symptomatic slow-acting drugs for OA (SYSADOA), unless stable dose for ≥3 months and require stable dose throughout the study.
-
Disease-modifying osteoarthritis drugs (DMOADs) previous three months.
-
Scheduled hand surgery during study participation.
-
Planning to start other treatments for hand OA in the study participation period.
-
Not able to adhere to the study visit schedule and protocol requirements.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Négyszeres
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Aktív összehasonlító: Methotrexate
Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks. Additional Folic acid 1mg prescribed daily. |
Methotrexate 2.5mg oral tablet. Folic acid |
|
Placebo Comparator: Placebo
3 capsules per week for two weeks, followed by 4 capsules the remaining weeks. Additional Folic acid 1mg prescribed daily. |
Placebo capsule Folic acid |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Finger pain on a visual analogue scale
Időkeret: 6 months
|
Difference in self-reported finger joint pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome. |
6 months
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Finger pain on a visual analogue scale
Időkeret: Month 1, 3, 9 and 12.
|
Self-reported finger pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 9 and 12.
|
|
Thumb pain on a visual analogue scale
Időkeret: Month 1, 3, 6, 9 and 12.
|
Self-reported thumb pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Pain most painful finger joint on a visual analogue scale
Időkeret: Month 1, 3, 6, 9 and 12.
|
Pain most painful finger joint last 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Patient-reported disease activity on a visual analogue scale
Időkeret: Month 1, 3, 6, 9 and 12.
|
Patient-reported disease activity last 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Pain all joints on a visual analogue scale
Időkeret: Month 1, 3, 6, 9 and 12.
|
Pain all joints last 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Hand diagram pain
Időkeret: Month 6.
|
Finger pain and thumb base pain (yes/no) on hand diagram |
Month 6.
|
|
Body diagram pain
Időkeret: Month 6.
|
Pain in other joints (yes/no) on body diagram |
Month 6.
|
|
AUSCAN
Időkeret: Month 1, 3, 6, 9 and 12.
|
Australian/Canadian hand index (AUSCAN), sum score 0-60, higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
OMERACT-OARSI responder criteria
Időkeret: Month 1, 3, 6, 9 and 12.
|
Fulfillment of Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) responder criteria. |
Month 1, 3, 6, 9 and 12.
|
|
EQ-5D
Időkeret: Month 1, 3, 6, 9 and 12.
|
Quality-adjusted life years (QALYs) based on the health-related utility scores measured by the generic instrument EuroQol 5 dimensions (EQ-5D), sum score 5-35, higher value indicate worse outcome, in addition to a 0-100 visual analogue scale where higher value indicate better outcome. |
Month 1, 3, 6, 9 and 12.
|
|
MHOQ
Időkeret: Month 6.
|
Michigan Hand Outcomes Questionnaire (MHOQ) pain and physical function subscales; function subscale range 10-50, higher value indicate worse outcome; task subscale range 17-85, higher value indicate worse outcome; work subscale range 5-25, higher value indicate worse outcome; pain subscale range 10-48, higher value indicate better outcome. |
Month 6.
|
|
Grip strength
Időkeret: Month 1, 3, 6, 9 and 12.
|
Grip strength (in kg; using a hand dynamometer) |
Month 1, 3, 6, 9 and 12.
|
|
HOOS-12
Időkeret: Month 6.
|
Hip disability and Osteoarthritis Outcome Score (HOOS)-12, range 12-60, higher value indicate worse outcome. |
Month 6.
|
|
KOOS-12
Időkeret: Month 6.
|
Knee injury and Osteoarthritis Outcome Score (KOOS)-12, range 12-60, higher value indicate worse outcome. |
Month 6.
|
|
Concomitant medication
Időkeret: Month 1, 3, 6, 9 and 12.
|
Concomitant medication |
Month 1, 3, 6, 9 and 12.
|
|
Tender and swollen joints
Időkeret: Month 1, 3, 6, 9 and 12.
|
Number of tender and swollen joints (range 0-30), higher values indicate more affected joints. |
Month 1, 3, 6, 9 and 12.
|
|
Physician-reported disease activity on a visual analogue scale
Időkeret: Month 1, 3, 6, 9 and 12.
|
Patient-reported disease activity on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Hand radiographs: Kellgren Lawrence
Időkeret: Month 6 and 12
|
Conventional radiographs: change in radiographic severity according to Kellgren-Lawrence scale, range 0-4 in each joint higher value indicate worse outcome. |
Month 6 and 12
|
|
Hand radiographs: Verbruggen-Veys anatomical phase scoring system
Időkeret: Month 6 and 12
|
Conventional radiographs: radiographic severity in finger joints according to Verbruggen-Veys anatomical phase scoring system, range 1-5; higher value indicate worse outcome. |
Month 6 and 12
|
|
Hand radiographs: OARSI atlas
Időkeret: Month 6 and 12
|
Conventional radiographs: rdiographic severity according to the Osteoarthritis Research Society International (OARSI) atlas for the presence/severity of osteophytes, joint space narrowing and erosions. |
Month 6 and 12
|
|
Hand MRI
Időkeret: Month 6
|
MRI of dominant hand: number of joints with synovitis and BMLs |
Month 6
|
|
Hand ultrasound
Időkeret: Month 1, 3, 6, 9 and 12.
|
Ultrasound: number of finger joints with synovial thickening and power Doppler signals. |
Month 1, 3, 6, 9 and 12.
|
|
Knee ultrasound
Időkeret: Month 6
|
Ultrasound: degree of synovitis in knee joints |
Month 6
|
|
Hip ultrasound
Időkeret: Month 6
|
Ultrasound: degree of synovitis in hip joints |
Month 6
|
|
Adverse events
Időkeret: Through study completion, maximum 12 months, in addition to 3 months after end of treatment.
|
Number of adverse events, serious adverse events, and withdrawals because of adverse events. |
Through study completion, maximum 12 months, in addition to 3 months after end of treatment.
|
Egyéb eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Sub-study: biopsy of knee OA
Időkeret: Month 6
|
Change in synovial cellular composition and gene expression with single-cell RNA sequencing analyses; subgroup analyses, n=16 patients |
Month 6
|
|
Sub-study: knee pain on a visual analogue scale
Időkeret: Month 6
|
Self-reported knee pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome. |
Month 6
|
|
Question about blinding
Időkeret: Month 12
|
The participants are asked which treatment they think they have received |
Month 12
|
|
HADS
Időkeret: Month 6
|
Hospital Anxiety and Depression Scales (HADS), range 0-42, higher value indicate worse outcome. |
Month 6
|
|
PCS
Időkeret: Month 6
|
Pain catastrophizing scale, range 0-12, higher value indicate worse outcome. |
Month 6
|
|
PSQ
Időkeret: Month 6
|
Pain Sensitivity Questionnaire (PSQ), range 0-170, higher value indicate worse outcome. |
Month 6
|
|
Anchor questions for MCII and PASS
Időkeret: Month 6
|
Questions about perceived improvement and acceptable symptom state that will be used to define minimally clinically important improvement and patient acceptable symptom state for other questionnaires |
Month 6
|
|
ASES
Időkeret: Month 6
|
Arthritis Self Efficacy Scale (ASES), range 10-100, higher value indicate better outcome. |
Month 6
|
|
Pain sensitization
Időkeret: Month 6
|
Pain sensitization: Pressure Pain Thresholds (PPT) by digital algometer; temporal summation by punctate probes; Conditioned Pain Modulation (CPM) by blood pressure ischemic test. |
Month 6
|
|
Soluble biomarkers of extracellular matrix turnover
Időkeret: Month 6 and 12
|
Markers of collagen degradation (s-COMP, s-C1M, s-C2M, s-C3M, s-CTX1, sHA), collagen synthesis (s-proC2), aggrecan degradation (s-huARGS) and inflammation (s-calprotectin, s- vimentin, s-hsCRP and s-CRPM); Inflammatory cytokines (IL-1β, IL-1ra, IL-4, IL-6, IL-10, IL-12, IL-17, IL-18, IL-21, IFN-γ, TNF-α, VEGF, GM-CSF, CCL2, CCL3, CCL4, CXCL10) and hormones (leptin and resistin). |
Month 6 and 12
|
|
Omics
Időkeret: Month 6 and 12
|
Omics analyses of whole blood |
Month 6 and 12
|
Együttműködők és nyomozók
Szponzor
Együttműködők
Nyomozók
- Tanulmányi szék: Tore K Kvien, MD, PhD, Professor Em.
Publikációk és hasznos linkek
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- DIA2020-01
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
The trialists and other study personnel that conceive of the study, and then plan, manage, monitor, analyze and publish it, will have access to IPD. Participants' identification code numbers are de-identified by replacing the original code number with a new random code number. Only the PI and project coordinator have access to this code.
The protocol, SAP, ICF, and CSR will be shared with regulatory agents as required.
Tanulmányi adatok/dokumentumok
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
az Egyesült Államokban gyártott és onnan exportált termék
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .